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The safety and efﬁcacy of 10/10 HLA antigen matched PBSC
HCT from unrelated donors (URD)s after nonmyeloablative con-
ditioning with ﬂudarabine (3 x 30 mg/m2) and 2 Gy TBI (FLU/2
Gy TBI) followed by cyclosporine (CSP) and MMF (both given
BID) for patients with hematologic malignancies ineligible for
conventional HCT was previously demonstrated (Maris, Blood
Vol 102, #6). Fifty-nine of the 71 pts who received PBSC grafts
had sustained engraftment. In that study, the half-life of mycophe-
nolate acid (active metabolite of MMF) was found to be 3 hours.
This suggested that TID dosing of MMF could improve postgraft-
ing immunosuppression and thereby increase engraftment rates.
Subsequently, a trial of dose escalated MMF (15 mg/kg TID) while
holding other HCT parameters constant was performed in 103 pts
given PBSC grafts from URDs after FLU/2 Gy TBI, CSP and
MMF, 15 mg/kg TID. The results in 69 patients with sufﬁcient
followup in this trial were compared to those in the previous 71 pts
given MMF BID. Median (med) age of TID MMF pts was 58
(range 17-70) years and that of BIDMMF pts was 54 (range 18-70)
years. The med follow-up of pts given MMF TID and BID was 9
and 25 months. The med neutrophil nadir was 100/l vs.740/l
(p  .01), but duration of absolute neutropenia was similar (8.5 vs
9 days, p  .43) for pts who received MMF TID and BID,
respectively. There were trends toward less graft rejection at 1 year
(7% vs.16%, p  .06) and higher peripheral blood donor CD3
chimerism at day 28 after HCT (90% vs 75%, p  .09) with TID
versus BID MMF. Other outcomes were not statistically different
between TID versus BID patient groups: The cumulative proba-
bilities (CP) of acute grades, II, III and IV GVHDwere 40%, 11%,
and 1% versus 41%, 10% and 3%, respectively. The CP of chronic
GVHD requiring therapy were 40% and 44%, respectively. The
Kaplan-Meier estimates at 1 year were 60% and 58% for overall
survival, and 44% and 44% for progression free survival, respec-
tively. The CP of relapse was 34% and 41%, respectively. The CP
of nonrelapse mortality (NRM) at day 100 and at 1 year were 9%
vs.11% and 22% vs.16%, respectively. We tentatively conclude
that MMF dosing for URD PBSC grafts after FLU/2 Gy TBI can
be safely increased from BID to TID without increasing toxicities,
NRM, or relapse rates. TID compared to BID dosing of MMF in
this setting may result in higher donor day 28 CD3 chimerism
values and sustained engraftment rates, while other outcomes were
comparable.
81
ONCE DAILY INTRAVENOUS BUSULFAN AS PART OF A BUSULFAN/
CYCLOPHOSPHAMIDE CONDITIONING REGIMEN FOR ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
Mates, M., Michalska, H., Hasegawa, W., Kiss, T., Daly, A., Loach, D.,
Messner, H., Lipton, J. Princess Margaret Hospital, Allogeneic Bone
Marrow Transplant Program, University of Toronto, Toronto, ON,
Canada.
Objective: Busulfan (Bu) is frequently used as part of myeloab-
lative conditioning regimens prior to stem cell transplantation
(SCT), especially to avoid total body irradiation. Hepatic venooc-
clusive disease (HVOD) is a well-recognized dose-limiting toxicity
for oral Bu-preparative regimens. The purpose of this review was
to evaluate the toxicity, efﬁcacy, 100-day mortality, overall and
disease free survival in patients treated with single daily dose
intravenous (iv) Bu as part of a Bu/Cyclophosphamide (Cy) con-
ditioning regimen for allogeneic SCT. Patients and Methods: 29
consecutive patients undergoing allogeneic SCT received iv Bu as
part of their conditioning between March 2002 and August 2003.
Conditioning consisted of iv Bu (3.2mg/kg once daily x 4 doses)
followed by high dose Cy and allogeneic SCT. The donors were
HLA-matched siblings (n  23), 1 antigen mismatched related
donors (n  1) and matched unrelated donors (n  5). All patients
received graft versus host disease (GVHD) prophylaxis consisting
of Cyclosporine A and Methotrexate. Results: 28 patients en-
grafted with a median time for neutrophil recovery of 21 days
(12,29) and median time for platelets recovery of 18 days (10,49).
14 patients (48.3%) developed HVOD, 10 mild (34.5%), 2 mod-
erate (6.9%) and 2 severe HVOD (6.9%). Acute GVHD grade
II-IV occurred in 18 patients (64.3%). 3 patients (10.3%) died in
the ﬁrst 100 days after the transplant, with 1 death due to severe
HVOD (3.4%), 1 due to graft failure (3.4%) and 1 to other
transplant related toxicity (3.4%). After a median follow up of 8
months (1,16) chronic GVHD occurred in 12 out of 24 evaluable
patients (50%), 2 patients relapsed (6.9%), 1 patient is still in a
partial remission (3.4%) and a total of 7 patients died (24.1%). 22
patients (75.9%) were alive at their last follow up. Overall survival
at 6 months was 84.5%, and at 1 year 69.4%. 6-month disease-free
survival was 80.7% and at 1 year 67.3%. Conclusions: Condition-
ing regimens with single daily dose iv Bu allowed consistent en-
graftment from related and unrelated donors. Only one graft fail-
ure occurred in a patient undergoing a second allogeneic SCT
from a second matched related donor. 14 patients met criteria for
HVOD, but the majority of them were mild. Treatment related
mortality was limited. Overall survival and disease-free survival
rates are encouraging thus meriting further studies for deﬁning the
role of iv Bu as a preferred substitute for oral Bu.
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SULTS IN RAPID FULL DONOR ENGRAFTMENT IN PEDIATRIC PATIENTS
WITH MALIGNANCY
Fry, T.J.1, Wayne, A.1, Fowler, D.2, Hakim, F.2, Love, C.1, Gress, R.2,
Bishop, M.2, Mackall, C.L.1 1. Pediatric Oncology Branch, NCI, NIH,
Bethesda, MD; 2. Experimental Transplantation and Immunology
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Background: There is limited experience with non-myeloabla-
tive (NM) allogeneic hematopoietic stem cell transplantation
(alloSCT) in pediatric pts with cancer. In comparison to adults,
children and adolescents have less immune depletion and improved
reconstitution after chemotherapy, which might increase the risk
of mixed donor hematopoietic chimerism after NM alloSCT. Pro-
longed periods of mixed chimerism may increase the risk of relapse
in highly proliferative pediatric cancers. Methods: Twelve pedi-
atric pts (age 7-20, median 14.5 years) with high-risk malignancies
(Hodgkin’s disease, ALL, AML, CML, rhabdomyosarcoma, Ew-
ing’s sarcoma) were treated with a novel immunoablative regimen.
Fludarabine-based induction chemotherapy was administered for
disease control and host immune depletion (1 to 3 cycles). This was
followed by pre-transplant conditioning with cyclophosphamide
(1,200 mg/m2/day) and ﬂudarabine (30 mg/m2/day) x 4 days with
or without melphalan (100 mg/m2 x 1 dose). Unmodiﬁed, G-CSF
mobilized peripheral blood stem cells collected from HLA-
matched siblings were employed (CD34 doses of 6.9-19 x 106/kg).
Results: The regimen was associated with sequential lymphocyte
depletion, although to a lesser degree than in 18 adult pts (age
33-67, median 50 years) treated on a parallel trial (Table 1). IL7
levels were inversely correlated with CD4 counts (r2  0.20, p 
0.0006). Hematopoietic recovery was rapid in all pts. Complete
donor lymphoid chimerism (97% by VNTR-PCR on CD3
sorted peripheral blood) was achieved in 9 of 11 pts by post-
transplant day (D) 14, while 2 had mixed chimerism that im-
proved between D  14 to D  28 (70%3 85%, 85%3 95%
Table. Outcomes after Nonmyeloablative Conditioning Using URDs:
TID vs BID MMF
TID MMF
(n  69)
BID MMF
(n  71) P
1 year Graft Rejection 7% 16% .06
Day 28 T-cell Chimerism 90% 75% .09
100 day aGVHD Grades
II, III, IV 40%, 11%, 1% 41%, 10%, 3% .61
1-year CGVHD 40% 44% .35
1-year NRM 22% 16% .59
1-year Overall Survival 60% 58% .88
1-year Progression Free
Survival 44% 44% .89
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